GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Osi Pharmaceuticals Inc. (OSIP) [hlAlert]

OSI Pharmaceuticals, Inc. (OSI) is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing unmet medical needs in oncology, diabetes and obesity. The Company's primary focus is oncology and its flagship product is Tarceva (erlotinib), a small
molecule inhibitor of the epidermal growth factor receptor (EGFR). OSI also has research and development programs in diabetes and obesity, which are conducted through Prosidion Limited, the Company's United Kingdom subsidiary. Roche Holding Ltd. and OSI announced that Tarceva (erlotinib) has been approved in Japan for the treatment of patients with nonresectable, recurrent and advanced non-small cell lung cancer (NSCLC), which is aggravated following chemotherapy. In December 2008, the Company acquired from 7TM Pharma A/S, a number of early stage research assets and a G-Protein coupled receptor (GPCR), technology platform.
.
( Total: 17 Current Stock Recommendations )
Osi Pharmaceuticals Inc.   (17)
Hold 53% Buy 47%
Related companies
DARA BIOSCIENCES   (2)
Buy 100%
CELSION CORP   (5)
Buy 100%
ATHERSYS INC   (7)
Buy 100%
ACURA PHARMACEUTICAL   (2)
Buy 100%
China Pharma   (2)
Buy 100%
BioSpecifics ...   (4)
Buy 100%
Derma Sciences, Inc.   (2)
Buy 100%
Oncogenex ...   (8)
Buy 100%
ARCA BIOPHARMA INC.   (1)
Buy 100%
PROLOR Biotech, Inc.   (5)
Buy 100%
Show  

Date (ET)MemberRatingYTD
Gains
 
11/30/2007  
Buy
up  85.09 %
6/1/2009  
Hold
  
7/31/2007  
Hold
  
2/20/2009  
Buy
up  85.09 %
11/10/2008  
Buy
up  85.09 %
11/18/2008  
Hold
  
3/2/2010  
Hold
up  82.09 %
6/16/2009  
Hold
  
3/3/2008  
Buy
up  85.09 %
5/17/2010  
Hold
up  84.77 %
6/19/2009  
None
  
12/5/2008  
Buy
up  85.09 %
8/14/2007  
Buy
up  85.09 %
3/13/2008  
Buy
up  85.09 %
3/2/2010  
Hold
up  82.09 %
1/3/2008  
Hold
  
6/24/2009  
Hold
  
12/4/2007  
Buy
up  85.09 %

* As of 4/15/2014 12:00 AM
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy